234 related articles for article (PubMed ID: 34520052)
61. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
62. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
63. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
64. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
65. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
66. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
67. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Steidl C; Shah SP; Woolcock BW; Rui L; Kawahara M; Farinha P; Johnson NA; Zhao Y; Telenius A; Neriah SB; McPherson A; Meissner B; Okoye UC; Diepstra A; van den Berg A; Sun M; Leung G; Jones SJ; Connors JM; Huntsman DG; Savage KJ; Rimsza LM; Horsman DE; Staudt LM; Steidl U; Marra MA; Gascoyne RD
Nature; 2011 Mar; 471(7338):377-81. PubMed ID: 21368758
[TBL] [Abstract][Full Text] [Related]
68. Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease: Two cases that highlight the combination of immunodeficiency and immune escape in the pathogenesis.
Tsuyuki Y; Kohno K; Inagaki Y; Sakai Y; Kosugi H; Takahashi E; Suzuki Y; Shimada S; Kato S; Takahara T; Satou A; Shimoyama Y; Nakamura S; Asano N; Sakakibara A
J Clin Exp Hematop; 2021; 61(3):173-179. PubMed ID: 34511545
[TBL] [Abstract][Full Text] [Related]
69. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
[TBL] [Abstract][Full Text] [Related]
70. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
71. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
Twa DD; Chan FC; Ben-Neriah S; Woolcock BW; Mottok A; Tan KL; Slack GW; Gunawardana J; Lim RS; McPherson AW; Kridel R; Telenius A; Scott DW; Savage KJ; Shah SP; Gascoyne RD; Steidl C
Blood; 2014 Mar; 123(13):2062-5. PubMed ID: 24497532
[TBL] [Abstract][Full Text] [Related]
72. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
[TBL] [Abstract][Full Text] [Related]
73. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
74. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Koh YW; Han JH; Yoon DH; Suh C; Huh J
Ann Hematol; 2017 Nov; 96(11):1883-1890. PubMed ID: 28842748
[TBL] [Abstract][Full Text] [Related]
75. The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.
Zijtregtop EAM; Tromp I; Dandis R; Zwaan CM; Lam KH; Meyer-Wentrup FAG; Beishuizen A
Pathol Oncol Res; 2022; 28():1610482. PubMed ID: 36032657
[TBL] [Abstract][Full Text] [Related]
76. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
77. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
78. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
[TBL] [Abstract][Full Text] [Related]
79. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
80. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ
Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]